hemophilia
Hemophilia is divided into two types: A and B. Hemophilia A is a bleeding disease caused by the deficiency of coagulation factor VIII, accounting for about 85% of congenital bleeding diseases. According to the report of the joint meeting of the World Health Organization (WHO) and the World Federation of Hemophilia (WHF) in 1990, the incidence of hemophilia A is about 15-20/100,000 people. According to statistics from European and American countries, it is about 5-10/100,000 people. The incidence of hemophilia A in China is about 3-4/100,000 people. Hemophilia B, also known as factor IX deficiency or Christmas disease, has an incidence of about 1.0-1.5/105, accounting for 15%-20% of hemophilia. The gene of factor IX is 34kb long, located on the long arm of chromosome X, with 8 exons and 7 introns. Factor IX is a plasma protein dependent on vitamin K, with a relative molecular weight of 56,000, and is synthesized in the liver. The treatment of hemophilia A and B is similar, using replacement therapy, and plasma, prothrombin complex concentrate (PCC), factor IX concentrate and recombinant factor IX products can be used.
-
Site of disease:
Spinal cord blood vessels -
Infectious :
Not contagious -
Frequent population:
Often develops in childhood -
Related symptoms:
Skin bleeding spots Intra-articular bleeding Muscle bleeding Wounds that do not heal after tooth extraction Joint swelling -
Concurrent disease:
Related Drugs
Aminocaproic acid tablets
Indication: It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. (1) Bleeding caused by trauma or surgery of organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, and thyroid glands, and bleeding caused by excessive amounts of tissue plasminogen activator (t-PA), streptokinase, or urokinase. (2) It can be used as an adjuvant treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophiliacs. (3) It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura, and leukemia. It has a significant effect on general chronic oozing; it has a poor effect on bleeding caused by abnormal coagulation function; and it has no hemostatic effect on severe bleeding, massive bleeding from wounds, and bleeding from cancer.
Manufacturer:
Shanghai Sine Pharmaceutical Laboratories Co., Ltd.
Aminocaproic acid tablets
Indication: It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. (1) Bleeding caused by trauma or surgery of organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, and thyroid glands, and bleeding caused by excessive amounts of tissue plasminogen activator (t-PA), streptokinase, or urokinase. (2) It can be used as an adjuvant treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophiliacs. (3) It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura, and leukemia. It has a significant effect on general chronic oozing; it has a poor effect on bleeding caused by abnormal coagulation function; and it has no hemostatic effect on severe bleeding, massive bleeding from wounds, and bleeding from cancer.
Manufacturer:
Zhejiang Kangle Pharmaceutical Co., Ltd.
Aminocaproic acid tablets
Indication: It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. (1) Bleeding caused by trauma or surgery of organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, and thyroid glands, and bleeding caused by excessive amounts of tissue plasminogen activator (t-PA), streptokinase, or urokinase. (2) It can be used as an adjuvant treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophiliacs. (3) It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura, and leukemia. It has a significant effect on general chronic oozing; it has a poor effect on bleeding caused by abnormal coagulation function; and it has no hemostatic effect on severe bleeding, massive bleeding from wounds, and bleeding from cancer.
Manufacturer:
Beijing Shuguang Pharm Co., Ltd.
Aminocaproic acid tablets
Indication: It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. (1) Bleeding caused by trauma or surgery of organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, and thyroid glands, and bleeding caused by excessive amounts of tissue plasminogen activator (t-PA), streptokinase, or urokinase. (2) It can be used as an adjuvant treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophiliacs. (3) It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura, and leukemia. It has a significant effect on general chronic oozing; it has a poor effect on bleeding caused by abnormal coagulation function; and it has no hemostatic effect on severe bleeding, massive bleeding from wounds, and bleeding from cancer.
Aminocaproic acid tablets
Indication: It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. (1) Bleeding caused by trauma or surgery of organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, and thyroid glands, and bleeding caused by excessive amounts of tissue plasminogen activator (t-PA), streptokinase, or urokinase. (2) It can be used as an adjuvant treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophiliacs. (3) It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura, and leukemia. It has a significant effect on general chronic oozing; it has a poor effect on bleeding caused by abnormal coagulation function; and it has no hemostatic effect on severe bleeding, massive bleeding from wounds, and bleeding from cancer.
Manufacturer:
Diaoyutai Pharmaceutical Group Jilin Changqing Pharmaceutical Co., Ltd.
Human prothrombin complex
Indication: This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.
Manufacturer:
Hualan Biological Engineering,Inc.
Human prothrombin complex
Indication: This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.
Manufacturer:
Hualan Biological Engineering,Inc.
Human prothrombin complex
Indication: This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.
Manufacturer:
Hualan Biological Engineering,Inc.
Human prothrombin complex
Indication: This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.
Manufacturer:
Hualan Biological Engineering,Inc.
Human prothrombin complex
Indication: This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.
Manufacturer:
Hualan Biological Engineering,Inc.
Related Ingredients
-
6-Aminocaproic acid list
60-32-2 -
N-T-BOC-ILE-GLU-GLY-ARG 7-AMIDO-4-METHYL-COUMARIN HYDROCHLORIDE list
102601-26-3